Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTER-EWING-1
2024-511989-36-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of vinorelbine and cyclophosphamide in Ewing sarcoma (4 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
vinorelbinecyclophosphamide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on 2024-511989-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511989-36-00.